A citation-based method for searching scientific literature

Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
Times Cited: 329



Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau, Robert Boulter, Aaron Cranston, Mark J O'Connor, Niall M B Martin, Piet Borst, Jos Jonkers. Proc Natl Acad Sci U S A 2008
Times Cited: 614




List of shared articles



Times cited

BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
Oliver Trusler, Jacob Goodwin, Andrew L Laslett. Biochim Biophys Acta Rev Cancer 2021
0

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
2

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.
Setor Amuzu, Euridice Carmona, Anne-Marie Mes-Masson, Celia M T Greenwood, Patricia N Tonin, Jiannis Ragoussis. Cancers (Basel) 2021
0

PARP1: Structural insights and pharmacological targets for inhibition.
Jacob O Spiegel, Bennett Van Houten, Jacob D Durrant. DNA Repair (Amst) 2021
0

BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Rachel Royfman, Emma Whiteley, Olivia Noe, Susan Morand, Justin Creeden, Laura Stanbery, Danae Hamouda, John Nemunaitis. Future Oncol 2021
0

Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Qian Zhong, Ying Xiong, Chen Ling, Yanping Qian, Xia Zhao, Hanshuo Yang. Exp Biol Med (Maywood) 2021
0

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
17

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Madalena Tarsounas, Patrick Sung. Nat Rev Mol Cell Biol 2020
47


Therapeutic applications of PARP inhibitors in ovarian cancer.
Hongyu Xie, Wenjie Wang, Bairong Xia, Weilin Jin, Ge Lou. Biomed Pharmacother 2020
9

PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Katherine C Kurnit, Monica Avila, Emily M Hinchcliff, Robert L Coleman, Shannon N Westin. Pharmacol Ther 2020
3

Biomarker-Guided Development of DNA Repair Inhibitors.
James M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, Alan D D'Andrea. Mol Cell 2020
29